Antitrust Chronicle® – Patents, Drugs & Antitrust
Spring 2014, Volume 4, Number 2
Dear Readers, This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to sell samples of restricted distribution […]
In this issue
Oct 1, 2021
Dec 22, 2015
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
Apr 29, 2014
In case you missed it...

March
This Chronicle brings together contributions that explore the evolving relationship between industrial policy, competition, regulation & technological change from complementary angles.

February
This month’s TechREG Chronicle focuses on online consumer protection, at a moment when regulators on both sides of the Atlantic are reassessing how legacy consumer-protection frameworks apply in digital, data-driven markets.

January
Tech banking charters have returned to the center of regulatory and strategic debate, driven by the convergence of digital assets, stablecoins, and the maturation of fintech business models.
See more Chronicles by year:
Featured News
Cisco in Advanced Talks to Acquire AI Security Startup Astrix for Up to $350 Million
Apr 12, 2026 by
CPI
European Commission Reviews Whether ChatGPT Falls Under EU Digital Services Act Rules
Apr 12, 2026 by
CPI
High-Stakes Trial Against Live Nation Enters Final Phase
Apr 12, 2026 by
CPI
Realtors Group to Pay $52 Million to Settle Homebuyer Antitrust Claims
Apr 10, 2026 by
CPI
Delaware Wants to be the Regulatory Home for Stablecoins
Apr 10, 2026 by
CPI